Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Plitidepsin in Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

Next Previous
Trial Profile

A Phase II Study of Plitidepsin in Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plitidepsin (Primary)
  • Indications T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors PharmaMar

Most Recent Events

  • 18 Jul 2018 Status changed from active, no longer recruiting to discontinued.
  • 25 May 2018 Status changed from recruiting to active, no longer recruiting.
  • 14 Jun 2016 According to a PharmaMar media release, T-cell-lymphoma is classified as a rare disease, and in consultation with the US Food and Drug Administration (FDA), the study has been designed with only one study arm.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top